Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer

BACKGROUND: The impact of primary tumor size on the therapeutic outcomes of EGFR‐tyrosine kinase inhibitors (TKIs) in advanced non‐small cell lung cancer (NSCLC) with EGFR mutation remains unclear. METHODS: A total of 291 consecutive patients with advanced EGFR‐mutant NSCLC administered first‐line E...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yingying, Gao, Guanghui, Chen, Xiaoxia, Tian, Qinrui, Wu, Fengying, Liu, Qian, Wang, Yan, Jiang, Tao, Liu, Yiwei, Li, Xuefei, Yang, Shuo, Xu, Chuan, Su, Chunxia, Zhou, Fei, Ren, Shengxiang, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449243/
https://www.ncbi.nlm.nih.gov/pubmed/30793872
http://dx.doi.org/10.1111/1759-7714.12986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449243/
https://www.ncbi.nlm.nih.gov/pubmed/30793872
http://dx.doi.org/10.1111/1759-7714.12986

Ejemplares similares